首页> 外文期刊>Regulatory peptides. >Newly developed angiotensin II-infused experimental models in vascular biology.
【24h】

Newly developed angiotensin II-infused experimental models in vascular biology.

机译:最新开发的血管紧张素II注入的血管生物学实验模型。

获取原文
获取原文并翻译 | 示例

摘要

Angiotensin II is a major vasoactive peptide in the renin-angiotensin system (RAS). In vitro evidence demonstrates that this peptide can modulate the function of various adhesion molecules, chemokines, cytokines and growth factors, and ultimately contributes to cell proliferation, hypertrophy and inflammation. Moreover, in vivo studies further support that angiotensin II induces several vascular alterations including sustained elevations of blood pressure, enhanced inflammatory response, increased medial thickness of the aortas, and formation of aortic dissection and aneurysms. Thus, it has been a long time that angiotensin II-induced hypertension, atherosclerosis and abdominal aortic aneurysms emerge as important experimental models with respect to vascular biology. Applications of these models to investigate the vascular diseases have dramatically improved our understanding in the pathogenesis of these diseases. However, the pathophysiology of angiotensin II in vivo remains to be determined in many other vascular diseases where angiotensin II has been implicated as the detrimental factor, at least in part due to the limit availability of animal models. Recently some new exciting experimental models based on angiotensin II infusion have been reported to replicate the human diseases, such as postmenopausal hypertension, preeclampsia, vascular remodeling, vascular aging and neovascularization. In this review, we will focus on the rationales and anticipated applications of these newly developed models, with special emphasis placed on those relevant to the vascular biology. We will also discuss the limitations of the method of chronic angiotensin II infusion and additional approaches to overcome these limitations. These experimental models will provide great opportunity for us to investigate the molecular mechanisms of angiotensin II and evaluate therapeutic approaches, particularly to finely tune the potential role of RAS activation in various vascular events using genetically engineered mice.
机译:血管紧张素II是肾素-血管紧张素系统(RAS)中的主要血管活性肽。体外证据表明,该肽可调节各种粘附分子,趋化因子,细胞因子和生长因子的功能,并最终促进细胞增殖,肥大和炎症。此外,体内研究进一步支持血管紧张素II诱导多种血管改变,包括持续升高的血压,增强的炎症反应,增加的主动脉内侧厚度以及主动脉夹层和动脉瘤的形成。因此,很长一段时间以来,血管紧张素II诱导的高血压,动脉粥样硬化和腹主动脉瘤已成为有关血管生物学的重要实验模型。这些模型在调查血管疾病中的应用极大地提高了我们对这些疾病的发病机理的认识。然而,在许多其他血管疾病中,血管紧张素II的体内病理生理学仍有待确定,其中血管紧张素II被认为是有害因素,至少部分是由于动物模型的局限性。最近,已经报道了一些基于血管紧张素II输注的令人兴奋的新实验模型,它们可以复制人类疾病,例如绝经后高血压,先兆子痫,血管重塑,血管衰老和新血管形成。在本文中,我们将重点介绍这些新开发模型的原理和预期应用,特别着重于与血管生物学相关的模型。我们还将讨论慢性血管紧张素II输注方法的局限性以及克服这些局限性的其他方法。这些实验模型将为我们提供巨大的机会,以研究血管紧张素II的分子机制并评估治疗方法,尤其是使用基因工程小鼠来微调RAS激活在各种血管事件中的潜在作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号